Cardiometabolic
Roche’s Nearly $2B Atavistik Bet Goes After Cardiometabolic Targets Other Drugs Struggle to Reach
Roche is paying Atavistik Bio $70 million upfront in a discovery partnership that could generate another $1.9 billion in milestones, plus royalties. The companies will use Atavistik’s allosteric discovery platform to pursue undisclosed cardiovascular, renal and metabolic targets, extending Roche’s rapidly expanding CVRM strategy into earlier and potentially harder-to-drug biology.
The Novo Nordisk Foundation is going global on cardiometabolic disease.
The baby sets the schedule. Postpartum diet advice still pretends mothers control the clock
Singapore wants healthcare AI that does not think like the West. Cardiometabolic care is its first real test
Metabolic syndrome may leave a signature in mitochondrial DNA. The biomarker race should not outrun the evidence
Beans for men, broccoli for women? The real cardiometabolic warning is that risk starts by 22
Why some “resistant” hypertension isn’t resistant at all, and what cardiology might be missing
Treating hypertension in pregnancy is possible. Making it routine care is the policy challenge
Ultra-processed food may leave a metabolic fingerprint in the blood.
Sugar substitutes were sold as metabolic shortcuts. The evidence is getting harder to ignore
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Cardiometabolic
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases